Dare Bioscience Stock Forum

$Dare Bioscience (DARE.US)$
Daré Bioscience Announces $2.5 Million Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Daré Bioscience received a $2.5 million grant installment for developing DARE-LARC1, a novel contraceptive technology. This payment is part of a larger $49 million grant agreement, of which $31.8 million has been received to date. DARE-LARC1 represents a potential new category of long-acting, reversible contraceptive featuring...

$Dare Bioscience (DARE.US)$ Reuters
3  mins ago
Daré Bioscience Announces Grant to Support Development of a Novel Non-Hormonal Contraceptive Candidate and Expansion of Ovaprene® Pivotal Study Clinical Trial Sites

$Dare Bioscience (DARE.US)$
Daré Bioscience Announces Grant to Support Development of a Novel Non-Hormonal Contraceptive Candidate and Expansion of Ovaprene® Pivotal Study Clinical Trial Sites
Daré Bioscience (NASDAQ: DARE) has secured a grant of up to $10.7 million from the Bill & Melinda Gates Foundation. The funding will support two key initiatives: the development of a novel non-hormonal intravaginal contraceptive product candidate and the expansion of clinical sites for the ongoing Ovapr...

$Dare Bioscience (DARE.US)$ Daré Bioscience Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health
 
DARE-HPV is a potential first-in-category treatment for human papillomavirus (HPV)-related cervical disease which could change the treatment paradigm for clinical HPV management.
 
Essentially all cervical cancer cases worldwide are caused by HPV infection.
 
SAN DIEGO, October 23, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE),...

$Aspira Women's Health (AWH.US)$
$Dare Bioscience (DARE.US)$
Aspira Women’s Health Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health

$Dare Bioscience (DARE.US)$
Daré Bioscience Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health
Daré Bioscience has been selected to receive a $10 million award from ARPA-H's Sprint for Women's Health program for the development of DARE-HPV, a potential first-in-category treatment for HPV-related cervical disease. The funding will be distributed over two years through the launchpad track for later-stage health solutions. DARE-HPV aims to provide an alternative to cur...

$Dare Bioscience (DARE.US)$ Daré Bioscience Announces Publication In The Journal Of Sexual Medicine, Safety Findings From The Phase 2b RESPOND Clinical Study Of Sildenafil Cream, 3.6%
Benzinga· 5 mins ago
Published data show that topical Sildenafil Cream, 3.6% was safe and well tolerated by women and their partners across 1,357 sexual experiences.
Use of topical Sildenafil Cream, 3.6% did not produce the common side effects of headache and flushing associated with oral sildenafil use in wo...